Compare Novavax Inc (NVAX) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Tripadvisor Inc Common Stock — how do they compare? Novavax Inc trades at $9.85 (market cap $1.62B), while Tripadvisor Inc Common Stock trades at $8.79 (market cap $1.03B). The key difference: Novavax Inc is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| NVAX | TRIP | |
|---|---|---|
Market Cap | $1.62B | $1.03B |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $19.14 |
52-Week Low | $6.22 | $8.82 |
Enterprise Value | $1.20B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Tripadvisor (TRIP) trades at $9.085, down 2.57% on the day, with a bearish technical signal and mixed earnings performance. The company reported Q2 2026 EPS of $0.35, missing estimates of $0.375, but maintains a strong gross margin of 92.11%. Recent news highlights insider selling and competitive pressures from AI travel tools, while the sale of TheFork subsidiary provides cash proceeds.
Outlook remains cautious with a consensus price target of $11.80, but risks include declining revenue forecasts for 2026, net cash outflows, and market share erosion. Upside hinges on Viator's growth and cost management, yet investor sentiment is tempered by execution challenges and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
